在自身免疫性疾病中使用CAR T细胞疗法:我们在哪里,我们要去哪里?
Marc Scherlinger1, Gaetane Nocturne2, Marko Radic3
1Rheumatology Department, Strasbourg University Hospital, Centre de référence pour les maladies auto-immunes systémiques Est - Sud Ouest (RESO), Strasbourg, France; UMR_S INSERM 1109, Immunorhumatologie Moléculaire, Strasbourg, France.
The Lancet. Rheumatology
|March 29, 2025
概括
化学抗原受体 (CAR) 疗法,最初用于血液癌症,现在正在探索自身免疫性疾病. 讨论了临床使用的挑战和未来步骤.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 类风湿病学 类风湿病学
背景情况:
- 基于CAR的疗法在治疗耐火性全身自身免疫性疾病方面表现有前途.
- 这些疗法最初是针对血液性恶性瘤开发的.
研究的目的:
- 批判性地审查目前关于基于CAR的治疗系统性自身免疫性疾病的数据.
- 讨论现有的挑战和临床实施的未来方向.
主要方法:
- 关于自身免疫性疾病中基于CAR的治疗现有文献的综述.
- 讨论各种CAR标,包括CD19,B细胞成熟抗原 (BCMA),CD138和纤维细胞激活蛋白.
- 探索CAR T调节细胞用于恢复免疫平衡.
主要成果:
- 针对B细胞向之外的自身免疫性疾病 (例如血细胞,非免疫性向) 的CAR疗法正在重新定位.
- 潜在的策略包括通过CD19,血细胞 (BCMA/CD138) 向B细胞,并使用CAR T调节细胞.
结论:
- 基于CAR的治疗对自身免疫性疾病有潜力,但面临着重大挑战.
- 解决关键问题对于将CAR疗法确立为系统性自身免疫性疾病的可行治疗选择至关重要.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Autoimmune Disorders
374
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
374
T Cell Types and Functions
756
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
756
Cell-mediated Immune Responses
66.6K
Overview
66.6K
T Cell Activation and Clonal Selection
622
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
622
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)